On March 20, 2020, Design Therapeutics announced that it is launching to create and develop a new class of therapies for patients with serious degenerative disorders caused by nucleotide repeat expansions. The company has closed a $45 million Series A financing led by SR One, with participation from Cormorant Asset Management, Quan Capital, and WestRiver Group, to advance its lead therapeutic candidate into clinical development for the treatment of Friedreich’s ataxia, and support advancement of its discovery programs for multiple other degenerative diseases, including fragile X syndrome and myotonic dystrophy.

A Wilson Sonsini Goodrich & Rosati team, including Michael Hostetler and Uale Taotafa, supported Design Therapeutics in the transaction and is representing Design Therapeutics in IP matters.

For more information, please see Design Therapeutics' press release.